<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.8" -->
<?xml-stylesheet href="https://onwar.se/lib/exe/css.php?s=feed" type="text/css"?>
<rdf:RDF
    xmlns="http://purl.org/rss/1.0/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:dc="http://purl.org/dc/elements/1.1/">
    <channel rdf:about="https://onwar.se/feed.php">
        <title>Onwards - peptide_dual-agonism</title>
        <description></description>
        <link>https://onwar.se/</link>
        <image rdf:resource="https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg" />
       <dc:date>2026-10-08T06:52:51+00:00</dc:date>
        <items>
            <rdf:Seq>
                <rdf:li rdf:resource="https://onwar.se/doku.php?id=peptide_dual-agonism:synergistic_engineering_in_mots_c_for_skeletal&amp;rev=1791306177&amp;do=diff"/>
                <rdf:li rdf:resource="https://onwar.se/doku.php?id=peptide_dual-agonism:synergistic_engineering_in_sermorelin_over&amp;rev=1791306243&amp;do=diff"/>
            </rdf:Seq>
        </items>
    </channel>
    <image rdf:about="https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg">
        <title>Onwards</title>
        <link>https://onwar.se/</link>
        <url>https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg</url>
    </image>
    <item rdf:about="https://onwar.se/doku.php?id=peptide_dual-agonism:synergistic_engineering_in_mots_c_for_skeletal&amp;rev=1791306177&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-10-06T17:02:57+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>synergistic_engineering_in_mots_c_for_skeletal</title>
        <link>https://onwar.se/doku.php?id=peptide_dual-agonism:synergistic_engineering_in_mots_c_for_skeletal&amp;rev=1791306177&amp;do=diff</link>
        <description>Metabolic research moves fast toward precision mitochondrial engineering. Scientists look closely at mitochondrial-derived peptides like MOTS-c. Understanding cellular bioenergetics, aging, and metabolic regulation reveals engineered variants and dual-agonism strategies as primary tools for maintaining metabolic health without losing lean mass. Skeletal muscle preservation remains a major hurdle in therapeutic weight management, athletic conditioning, and longevity science. Standard intervention…</description>
    </item>
    <item rdf:about="https://onwar.se/doku.php?id=peptide_dual-agonism:synergistic_engineering_in_sermorelin_over&amp;rev=1791306243&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-10-06T17:04:03+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>synergistic_engineering_in_sermorelin_over</title>
        <link>https://onwar.se/doku.php?id=peptide_dual-agonism:synergistic_engineering_in_sermorelin_over&amp;rev=1791306243&amp;do=diff</link>
        <description>Introduction to Growth Hormone Secretagogue Technology

The world of endocrine pharmacology has shifted dramatically over recent decades, moving far beyond crude animal-derived hormone replacements into precision-engineered synthetic peptides. At the forefront of this shift sit growth hormone secretagogues (GHS), molecules designed to stimulate the natural production and pulsatile release of growth hormone (GH) from the anterior pituitary gland. Among these compounds, Sermorelin has always held …</description>
    </item>
</rdf:RDF>
